EA202190308A1 - Применение пролекарств рилузола для лечения болезни альцгеймера - Google Patents

Применение пролекарств рилузола для лечения болезни альцгеймера

Info

Publication number
EA202190308A1
EA202190308A1 EA202190308A EA202190308A EA202190308A1 EA 202190308 A1 EA202190308 A1 EA 202190308A1 EA 202190308 A EA202190308 A EA 202190308A EA 202190308 A EA202190308 A EA 202190308A EA 202190308 A1 EA202190308 A1 EA 202190308A1
Authority
EA
Eurasian Patent Office
Prior art keywords
riluzole
disease
alzheimer
drugs
treatment
Prior art date
Application number
EA202190308A
Other languages
English (en)
Inventor
Владимир Корик
Роберт Берман
Ирфан Куреши
Original Assignee
Биохэйвен Терапьютикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биохэйвен Терапьютикс Лтд. filed Critical Биохэйвен Терапьютикс Лтд.
Publication of EA202190308A1 publication Critical patent/EA202190308A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Abstract

Раскрываются способы лечения болезни Альцгеймера путем введения пациенту, нуждающемуся в этом, пролекарства рилузола, такого как трорилузол. Также раскрываются фармацевтические композиции и наборы, включающие в себя пролекарства рилузола.
EA202190308A 2018-07-22 2019-07-20 Применение пролекарств рилузола для лечения болезни альцгеймера EA202190308A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22
PCT/US2019/042718 WO2020023324A1 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Publications (1)

Publication Number Publication Date
EA202190308A1 true EA202190308A1 (ru) 2021-05-19

Family

ID=69181140

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190308A EA202190308A1 (ru) 2018-07-22 2019-07-20 Применение пролекарств рилузола для лечения болезни альцгеймера

Country Status (14)

Country Link
US (1) US20210290599A1 (ru)
EP (1) EP3823616A4 (ru)
JP (1) JP2021530543A (ru)
KR (1) KR20210034621A (ru)
CN (1) CN112469408A (ru)
AU (1) AU2019310013A1 (ru)
BR (1) BR112021000768A2 (ru)
CA (1) CA3107215A1 (ru)
EA (1) EA202190308A1 (ru)
IL (1) IL280177A (ru)
MX (1) MX2021000515A (ru)
PH (1) PH12021550043A1 (ru)
SG (1) SG11202100385YA (ru)
WO (1) WO2020023324A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022076321A1 (en) * 2020-10-05 2022-04-14 Icahn School Of Medicine At Mount Sinai Riluzole for the treatment of alzheimer's disease
WO2022155564A1 (en) * 2021-01-18 2022-07-21 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
WO2022178425A1 (en) * 2021-02-22 2022-08-25 Yale University Targeted bifunctional degraders
WO2023165465A1 (zh) * 2022-03-01 2023-09-07 暨南大学 利鲁唑在治疗少精症中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2411545A1 (en) * 2000-06-14 2002-01-03 Medarex, Inc. Tripeptide prodrug compounds
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
EP3079692A4 (en) * 2013-12-09 2017-10-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
WO2016085998A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
BR112017018832B1 (pt) * 2015-03-03 2023-12-26 Biohaven Pharmaceutical Holding Company Ltd Profármacos de riluzol e seu uso e composição
MX2018013868A (es) * 2016-05-20 2019-02-21 Biohaven Pharm Holding Co Ltd Uso de agentes de modulacion de glutamato con inmunoterapias para tratar cancer.
US20190209532A1 (en) * 2016-08-10 2019-07-11 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use

Also Published As

Publication number Publication date
JP2021530543A (ja) 2021-11-11
EP3823616A4 (en) 2022-05-04
KR20210034621A (ko) 2021-03-30
CA3107215A1 (en) 2020-01-30
EP3823616A1 (en) 2021-05-26
MX2021000515A (es) 2021-06-08
CN112469408A (zh) 2021-03-09
PH12021550043A1 (en) 2021-09-20
WO2020023324A1 (en) 2020-01-30
US20210290599A1 (en) 2021-09-23
SG11202100385YA (en) 2021-02-25
IL280177A (en) 2021-03-01
BR112021000768A2 (pt) 2021-05-11
AU2019310013A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
CY1121062T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση της νοσου alzheimer
EA201800064A1 (ru) 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
BR112016025997A8 (pt) compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica
PH12020551425A1 (en) Rimegepant for cgrp related disorders
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
MX2021003152A (es) Piridazinonas y sus metodos de uso.
EA202190544A1 (ru) Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний
PH12020550583A1 (en) Use of riluzole prodrugs to treat ataxias
EA201790315A1 (ru) Модуляторы x-рецепторов печени
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
EA201890460A1 (ru) Композиции и способы лечения и предотвращения нейродегенеративных расстройств
BR112017027285A2 (pt) ?cocristal, composição farmacêutica e método para o tratamento de uma doença?
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение